Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2010-10-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3
NCT06595030
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
NCT04073628
A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1
NCT06356337
Light Therapy for Chronic Insomnia in General Practice
NCT04612192
Methodology Issues in a Tailored Light Treatment for Persons With Dementia
NCT01816152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Light is the most powerful signal from the environment that influences and regulates daily biological rhythms. It is well-established that the irradiance, duration, and timing of light exposure all affect the response of the circadian system. While it was once thought that these responses were mediated through the visual system, it is now known that there is a network of intrinsically photosensitive retinal ganglion cells (ipRGCs) that mediate circadian responses to light. Other new studies have demonstrated that recent light exposure history affects the circadian response to light in humans.
These recent findings have important implications for the use of light to treat circadian rhythm disorders, including delayed and advanced sleep phase disorders, shift work sleep disorder, and jet lag, and they may also have relevance for the use of light to treat seasonal affective disorder. Up to now, little attention has been paid to the duration or intensity of light exposure prior to such light treatments. The investigators now have evidence that the human circadian system can become desensitized to light during long exposures and evidence that it can be sensitized to light by prior exposure to dim light. These recent findings suggest that light treatment protocols that sensitize the circadian system prior to the light treatment will be more effective than those currently in use.
The 13-day inpatient studies the investigators propose will examine the effect on the human circadian system of different durations of dim-light sensitization prior to a standardized light treatment. These results will be compared within subjects in a randomized cross-over design study in which each subject will receive a control treatment and a light treatment with prior dim-light sensitization. The investigators will also include circadian phase disorder patients to test these mechanisms in the target patient population. Our findings will provide an important step in understanding how new knowledge about the circadian photoreceptive system can be used to refine and provide better treatment options for circadian rhythm disorders.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sensitization duration 1.375h
This group will experience a 1.375h sensitization duration prior to the 12h light exposure
light exposure
12-hour light exposure of approximately 200 lux
sensitization duration 5.5h
This group will experience a 5.5h sensitization duration prior to the 12h light exposure
light exposure
12-hour light exposure of approximately 200 lux
sensitization duration 22h
This group will experience a 22h sensitization duration prior to the 12h light exposure
light exposure
12-hour light exposure of approximately 200 lux
sensitization duration 0.33h
This group will experience a 0.33h sensitization duration prior to the 12h light exposure
light exposure
12-hour light exposure of approximately 200 lux
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
light exposure
12-hour light exposure of approximately 200 lux
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* non-smokers
* completion of medical, psychological, ophthalmological, and sleep screening tests
* able to spend 13 consecutive days/nights in the laboratory
Exclusion Criteria
* history of eye injury, eye surgery, or visual disorder (corrective lenses are acceptable)
* history of sleep disorder or regular use of sleep-promoting medication
* current prescription, herbal, or over-the-counter medication use (oral contraceptives are acceptable)
21 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeanne Duffy
Associate Neuroscientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles A Czeisler, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Jeanne F Duffy, PhD
Role: STUDY_DIRECTOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-P-000346
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.